<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0510222690
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADENURIC 80 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FEBUXOSTAT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        78.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Algorithm SAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M04AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Adenuric&reg; tablet contain the active substance febuxostat, and are used to treat gout, which is associated with an excess if chemical called uric acid (urate) in the body indicated for the chronic</p><p>management of hyperuricemia in patients with gout.<br />In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage.<br />Adenuric&reg; works by reducing uric acid levels. Keeping uric acid levels low by taking Adenuric&reg; once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long period can also shrink tophi.<br />Adenuric&reg; 120 mg tablets is also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers.<br />When chemotherapy is given, cancer cells are destroyed, and uric acid levels increase in the blood accordingly, unless the formation of uric acid is prevented.<br />Adenuric&reg; is indicated for adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Adenuric&reg;:<br />If you are allergic (hypersensitive) to febuxostat, or any of the other ingredients of this medicine (listed in section 6).<br />Warnings and precautions<br />Take special care with Adenuric&reg;:<br />Tell your doctor before you start to take this medicine:<br />- If you have or have had heart failure, heart problems or stroke<br />- If you have or have had renal disease and/or serious<br />allergic reaction to Allopurinol (a medication used for the treatment of Gout)</p><p>- If you have or have had liver disease or liver function test abnormalities<br />- If you are being treated for high uric acid levels as a result of Lesch-Nyhan syndrome (a rare inherited condition in which there is too much uric acid in the blood)<br />- If you have thyroid problems<br />Should you experience allergic reactions to Adenuric &reg;, stop taking this medicine (see also section 4).<br />Possible symptoms of allergic reactions might be:<br />- rash including severe forms (e.g. blisters, nodules, itchy-exfoliative rash), itchiness<br />- swelling of limbs or face<br />- difficulties in breathing<br />- fever with enlarged lymph nodes<br />- but also serious life threatening allergic conditions with cardiac and circulatory arrest.<br />Your doctor might decide to permanently stop treatment with Adenuric&reg;.<br />There have been rare reports of potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the use of Adenuric &reg;, appearing initially as reddish target-like spots or circular patches often with central blister on the trunk. It may also include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). The rash may progress to widespread blistering or peeling of the skin.<br />If you have developed Stevens-Johnson Syndrome with the use of febuxostat, you must not be restarted on Adenuric &reg; at any time. If you developed a rash or these skin symptoms, seek immediate advice from a doctor and tell that you are taking this medicine.<br />If you are having a gout attack at the moment (a sudden onset of severe pain, tenderness, redness, warmth and swelling in a joint), wait for the gout attack to subside before first starting treatment with Adenuric&reg;.<br />For some people, gout attacks may flare up when starting certain medicines that control uric acid levels. Not everyone gets flares, but you could get a flare-up even if you are taking Adenuric&reg; and especially during the first weeks or months of</p><p>treatment. It is important to keep taking Adenuric&reg; even if you have a flare, as Adenuric&reg; is still working to lower uric acid. Over time, gout flares will occur less often and be less painful if you keep taking Adenuric&reg; every day.<br />Your doctor will often prescribe other medicines, if they are needed, to help prevent or treat the symptoms of flares (such as pain and swelling in a joint).<br />In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with Adenuric&reg; for Tumor Lysis Syndrome.<br />Your doctor may ask you to have blood tests to check that your liver is working normally.<br />Children and adolescents:<br />Do not give this medicine to children under the age of 18 because the safety and efficacy have not been established.<br />Other Medicines and Adenuric &reg;<br />Please tell your doctor or pharmacist if you are taking, or have recently taken or might take, any other medicines, including medicines obtained without a prescription.<br />It is especially important to tell your doctor or pharmacist if you are taking medicines containing any of the following substances as they may interact with Adenuric&reg; and your doctor may wish to consider necessary measures:<br />- Mercaptopurine (used to treat cancer)<br />- Azathioprine (used to reduce immune response)<br />- Theophylline (used to treat asthma).<br />Pregnancy and breastfeeding:<br />It is not known if Adenuric&reg; may harm your unborn child. Adenuric&reg; should not be used during pregnancy. It is not known if Adenuric&reg; may pass into human breast milk. You should not use</p><p>Adenuric&reg; if you are breastfeeding, or if you are planning to breastfeed.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Driving and using machines:<br />Be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment and should not drive or operate machines if affected.<br />Adenuric&reg; contains lactose:<br />Adenuric&reg; tablets contain lactose (a type of sugar). If you have been told that you have an intolerance to some sugars contact your doctor before taking this medicine.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The usual dose is one tablet daily.</p><p>The tablets should be taken by mouth and can be taken with or without food.</p><p>&nbsp;</p><p>&bull; Gout:</p><p>Adenuric&reg; is available as either an 80 mg tablet or a 120 mg tablet. Your doctor will have prescribed the strength most</p><p>suitable for you.</p><p>Continue to take Adenuric&reg; every day even when you are not experiencing gout flare or attack.</p><p>&nbsp;</p><p>&bull; Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy:</p><p>Adenuric&reg; is available as a 120 mg tablet.</p><p>Start taking Adenuric&reg; two days before chemotherapy and</p><p>continue its use according to your doctor&rsquo;s advice. Usually</p><p>treatment is short-term.</p><p>The score line on the 80mg tablet is only there to help you break the tablet if you have difficulty swallowing it whole.</p><p>If you take more Adenuric&reg; than you should:</p><p>In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.</p><p>&nbsp;</p><p>If you forget to take Adenuric&reg;:</p><p>If you miss a dose of Adenuric&reg; take it as soon as you</p><p>remember unless it is almost time for your next dose, in which case miss out the forgotten dose and take your next dose at the</p><p>normal time. Do not take a double dose to make up for a</p><p>forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Adenuric&reg;:</p><p>Do not stop taking Adenuric&reg; without the advice of your doctor even if you feel better. If you stop taking Adenuric&reg; your uric acid levels may begin to rise and your symptoms may worsen due to the formation of new crystals of urate in and around your joints and kidneys.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Stop taking this medicine and contact your doctor immediately or go to an emergency department nearby if the following rare (may affect up to 1 in 1,000 people) side<br />effects occur, because a serious allergic reaction might follow<br />- anaphylactic reactions, drug hypersensitivity (see also section 2 &ldquo;Warnings and precautions&rdquo;)<br />- potentially life-threatening skin rashes characterized by formation of blisters and shedding of the skin and inner surfaces of body cavities, eg. mouth and genitals, painful ulcers in&nbsp;the mouth and/or genital areas, accompanied by fever, sore throat and fatigue (Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), rise of the white-cells count in the blood (drug reaction with eosinophilia and systemic symptoms-DRESS) (see section 2)<br />- generalised skin rashes<br />Common side effects (may affect up to 1 in 10 people) are:<br />abnormal liver test results, diarrhea, headache, rash (including various types of rash, please see below under &ldquo;uncommon&rdquo; and &ldquo;rare&rdquo; sections) nausea, increase in gout symptoms and localized swelling due to retention of fluids in tissues (oedema).<br />Other side effects which are not mentioned above are listed below.<br />Uncommon side effects (may affect up to 1 in 100 people) are:<br />- decreased appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive thirst, increased blood fat levels, weight increase<br />- loss of sex drive<br />- difficulty in sleeping, sleepiness<br />- dizziness, numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia), altered sense of taste, diminished sense of smell (hyposmia)<br />- abnormal ECG heart tracing, irregular or rapid heartbeats, feeling your heart beat (palpitation)<br />- hot flushes or flushing (e.g. redness of the face or neck), increased blood pressure,<br />bleeding (hemorrhage, seen only in patients taking chemotherapy for blood disorders)<br />- cough, shortness of breath, chest discomfort or pain,<br />inflammation of nasal passage and/or throat (upper<br />respiratory tract infection), bronchitis&nbsp;dry mouth, abdominal pain/discomfort or wind, heartburn/<br />indigestion, constipation, more frequent passing of stools, vomiting, stomach discomfort<br />- itching, hives, skin inflammation, skin discolouration, small red or purple spot on the skin, small, flat red spots on the skin, flat, red area on the skin that is covered with small confluent bumps, rash, areas of redness and spots on the skin, other type of skin conditions<br />- muscle cramp, muscle weakness, pain/ache in muscles/joints, bursitis or arthritis (inflammation of joints usually accompanied by pain, swelling and/or stiffness), pain in extremity, back pain, muscle spasm<br />- blood in the urine, abnormal frequent urination, abnormal urine tests (increased level of proteins in the urine), a reduction in the ability of the kidneys to function properly<br />- fatigue, chest pain, chest discomfort<br />- stones in the gallbladder or in bile ducts (cholelithiasis)<br />- increase in blood thyroid stimulating hormone (TSH) level<br />- changes in blood chemistry or amount of blood cells or platelets (abnormal blood test results)<br />- kidney stones<br />- erectile difficulties<br />Rare side effects (may affect up to 1 in 1,000 people) are:<br />- muscle damage, a condition which on rare occasions can be serious. It may cause muscle problems and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown. Contact your doctor immediately if you experience muscle pain, tenderness or weakness.<br />- severe swelling of the deeper layers of the skin, especially around the lips, eyes, genitals, hands, feet or tongue, with possible sudden difficult breathing<br />- high fever in combination with measles-like skin rash,</p><p>enlarged lymph nodes, liver enlargement, hepatitis (up to liver failure), rise of the white-cells count in the blood (leukocytosis, with or without eosinophilia)<br />- reddening of the skin (erythema), rash in various types (e.g. itchy, with white spots, with blisters, with blisters containing pus, with shedding of the skin, measles-like rash), widespread erythema, necrosis, and bullous detachment of the epidermis and mucous membranes, resulting in exfoliation and possible sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis)<br />- nervousness<br />- feeling thirsty<br />- ringing in the ears<br />- blurred vision, change in vision<br />- hair loss<br />- mouth ulceration<br />- inflammation of the pancreas: common symptoms are<br />abdominal pain, nausea and vomiting<br />- increased sweating<br />- weight decrease, increased appetite, uncontrolled loss of appetite (anorexia)<br />- muscle and/or joint stiffness<br />- abnormally low blood cell counts (white or red blood cells or platelets)<br />- urgent need to urinate<br />- changes or decrease in urine amount due to inflammation in the kidneys (tubulointerstitial nephritis)<br />- inflammation of the liver (hepatitis)<br />- yellowing of the skin (jaundice)<br />- liver damage<br />- increased level of creatine phosphokinase in blood (an indicator of muscle damage)<br />-sudden cardiac death<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store in the original package.<br />Do not store above 30&deg;C.<br />Do not use after the expiry date which is stated on the carton and the tablet blister foil after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is febuxostat.</p><p>Each tablet contains 80 mg or 120 mg of febuxostat.</p><p>The other ingredients are:</p><p>Tablet core: lactose monohydrate, microcrystalline cellulose, magnesium stearate, hydroxypropylcellulose, croscarmellose sodium and colloidal hydrated silica.</p><p>Film-coating: Opadry II yellow, 85F42129 containing: polyvinyl alcohol, titanium dioxide (E171), macrogols 3350, talc and iron oxide yellow (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Adenuric® film-coated tablets are pale yellow to yellow in colour and capsule shaped. 
The 80 mg film-coated tablets are marked on one side with ‘80’, with a break line on the other side. ­­­­ The 120 mg film-coated tablets are marked on one side with ‘120’. 
Adenuric® is supplied in 2 blisters of 14 tablets (28 tablet pack).
Not all presentations may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder And Final Batch Releaser:<br />ALGORITHM S.A.L. Zouk Mosbeh, Lebanon.<br />Manufacturer:<br />ALGORITHM S.A.L. Zouk Mosbeh, Lebanon.<br />Under license from Teijin Pharma Limited, Tokyo, Japan.<br />Adenuric is a trademark of Teijin Limited, Tokyo, Japan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rev. No. 04/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص أدينوريكم على المادة الفعّالة فيبوكسوستات، وتُستخدم لعلاج النقرس،<br />الذي يرتبط بزيادة مادة كيميائية تسمّى حمض اليوريك (يورات) في الجسم، وتُستعمل<br />للعلاج على المدى الطويل لفرط حمض يوريك الدم لدى المرضى الذين يعانون من<br />النقرس.<br />لدى بعض الأشخاص، تتراكم كميّة حمض البوليك في الدم وقد تصبح عالية جدًا لكي<br />تبقى قابلة للذوبان. عند حصول هذا، قد تتشكّل بلورات يورات في المفاصل والكليتين<br />وحولها. يمكن أن تسبّب هذه البلورات ألمًا مفاجئًا وحادًا واحمرارًا وحرارة وتورّمًا<br />في مفصل (ما يُعرف بنوبة نقرس). وفي حال عدم المعالجة، قد تتشكّل ترسّبات أكبر<br />تُسمّى حُصيبات في المفاصل وحولها. قد تسبّب هذه الحُصيبات ضررًا في المفاصل<br />والعظام.<br />يعمل أدينوريكم عبر تخفيض مستويات حمض البوليك. فإبقاء مستويات حمض<br />البوليك منخفضة عبر أخذ أدينوريكم مرّة واحدة في اليوم يوقف تراكم البلورات<br />ويخفّف العوارض مع الوقت. كما أنّ إبقاء مستويات حمض البوليك منخفضة بما يكفي<br />لمدّة كافية يمكن أن يقلّص حجم الحُصيبات.<br />تُستعمل أيضًا أقراص أدينوريكم ۱۲۰ ملغرام لعلاج والوقاية من ارتفاع مستويات<br />حمض اليوريك الذي يمكن أن يحدث عندما تبدأ بتلقّي علاجًا كيميائيًا لسرطان الدم.<br />عندما يُعطى العلاج الكيميائي، تُدمّر الخلايا السرطانيّة، فتزداد مستويات حمض</p><p dir="RTL">اليوريك في الدم كنتيجة لذلك، ما لم يتمّ منع تشكّل حمض اليوريك.<br />يُستعمل أدينوريكم لدى البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ أدينوريكم:<br />إذا كنت تعاني من فرط حساسيّة ضدّ الفيبوكسوستات أو ضدّ أيّ مكوّن آخر من<br />.( مكوّنات هذا الدواء (المكوّنات مذكورة في القسم ٦<br />التحذيرات والاحتياطات:<br />إعتمد عناية خاصة مع أدينوريكم:<br />أعلم طبيبك قبل أن تبدأ بأخذ هذا الدواء:<br />- إذا كنت مصابًا حاليًا أو أُصبت سابقًا بقصور قلبي، بمشاكل في القلب أو سكتة<br />دماغية<br />- إذا كنت مصابًا حاليًا أو أُصبت سابقًا بمرض كلوي و/أو بارتكاس تحسسي حاد ضدّ<br />الألوبورينول (دواء يُستعمل لعلاج النقرس)<br />- إذا كنت مصابًا حاليًا أو أُصبت سابقًا بمرض في الكبد أو بعدم انتظام في الوظيفة<br />الكبديّة<br />- إذا كنت تُعالج لأنّ لديك مستويات عالية من حمض البوليك كنتيجة لمتلازمة ليش-<br />نيهان (حالة نادرة وراثيّة تكون فيها مستويات حمض البوليك في الدم مرتفعة جدًا)<br />- إذا كنت تعاني من مشاكل في الغدّة الدرقيّة<br />إذا أُصبت بارتكاسات تحسسيّة ضدّ أدينوريكم، توقّف عن أخذ هذا الدواء (راجع القسم<br />٤ كذلك).<br />قد تكون العوارض المحتملة للارتكاسات التحسسيّة على النحو الآتي:<br />- طفح يتضمّن أشكالاً حادة (مثلاً بثور، عُقيدات، طفح تقشّري يسبّب الحكّة)، حكّة<br />- تورّم الأطراف أو الوجه<br />- صعوبات في التنفّس<br />- حمّى مع تضخّم العقد اللمفاويّة<br />- لكن أيضًا حالات تحسسيّة تهدّد الحياة مع توقّف قلبيّ ودوراني.<br />قد يقرّر طبيبك إيقاف العلاج بأدينوريكم بشكل دائم.<br />أفيد عن حالات نادرة من الطفح الجلدي الذي قد يهدّد الحياة (متلازمة ستيفنز-<br />جونسون) مع استعمال أدينوريكم تظهر أساسًا على شكل بقع ضاربة إلى الحمرة تشبه<br />الهدف أو بقع دائريّة غالبًا ما يكون لها نفطة مركزيّة على الجذع. قد تتضمّن هذه<br />الحالة أيضًا تقرّحات في الفم والحلق والأنف والأعضاء التناسليّة والتهاب الملتحمة<br />(تورّم واحمرار العينين). قد يتطوّر الطفح فيصبح تنفّطًا واسع النطاق أو تقشّرًا في<br />الجلد.<br />إذا أُصبت بمتلازمة ستيفنز-جونسون من جراء استعمال الفيبوكسوستات يجب عدم<br />علاجك بأدينوريكم مجددًا. إذا أُصبت بطفح أو بالعوارض الجلديّة هذه، استشر الطبيب<br />على الفور وأعلمه بأنّك تأخذ هذا الدواء.<br />إذا كنت تتعرّض لنوبة نقرس في الوقت الحالي (ألم مفاجئ وحاد واحمرار وحرارة<br />وتورّم في أحد مفاصلك)، انتظر حتّى تهمد نوبة النقرس قبل البدء بالعلاج بأدينوريكم.</strong></p><p dir="RTL"><strong>بالنسبة إلى بعض الأشخاص، قد تنطلق نوبات النقرس عند البدء باستعمال بعض<br />الأدوية التي تتحكّم بمستويات حمض البوليك. لا يُصاب المرضى كلّهم بالنوبات ولكن<br />يمكن أن تتعرّض لنوبة حتّى ولو كنت تأخذ أدينوريكم وبخاصة في خلال الأسابيع<br />أو الأشهر الأولى من العلاج. من المهمّ الاستمرار بأخذ أدينوريكم حتّى ولو أُصبت<br />بنوبة لأنّ أدينوريكم يعمل لتخفيض حمض البوليك. ومع الوقت، سوف ينخفض معدّل<br />حصول النوبات وسوف تكون هذه النوبات أخفّ ألمًا إذا واصلت أخذ أدينوريكم كلّ<br />يوم.<br />غالبًا ما سيصف لك طبيبك أدوية أخرى في حال الحاجة إليها وذلك للمساعدة على<br />الحؤول دون حصول العوارض أو لعلاج هذه العوارض (مثل الألم والتورّم في<br />مفصل).<br />لدى المرضى الذين تكون مستويات اليورات عالية لديهم (مثلاً الذين يخضعون لعلاج<br />كيميائي للسرطان)، يمكن أن يؤدّي العلاج بأدوية مخفّضة لحمض اليوريك إلى تراكم<br />الزانثين في المسالك البوليّة، مع إمكانيّة تشكّل حصى، حتّى ولو لم يُلاحظ ذلك لدى<br />المرضى المعالجين بأدينوريك لمتلازمة انحلال الورم.<br />قد يطلب منك طبيبك إجراء فحوصات دم للتأكّد من أنّ كبدك يعمل بصورة طبيعيّة.<br />الأطفال والمراهقون:<br />لا تعطِ هذا الدواء للأطفال ما دون ال ۱۸ من العمر لأنّه لم يتمّ التثبّت من سلامته<br />وفعاليّته.<br />الأدوية الأخرى وأدينوريكم:<br />الرجاء أن تُعلم طبيبك أو الصيدلي إذا كنت تأخذ حاليًا، أخذت مؤخّرًا أو قد تأخذ أيّ<br />أدوية أخرى بما فيها تلك التي حصلت عليها بدون وصفة طبيّة.<br />من المهمّ بشكل خاص أن تُعلم طبيبك أو الصيدلي إذا كنت تأخذ أدوية تحتوي على<br />إحدى المواد التالية لأنّها قد تتفاعل مع أدينوريكم وقد يرغب طبيبك في اتخاذ إجراءات<br />ضروريّة:<br />- المركابتوبورين (المستعمل لعلاج السرطان)<br />- الأزاثيوبرين (المستعمل للحدّ من الاستجابة المناعيّة)<br />- الثيوفيلين (المستعمل لعلاج الربو).<br />الحمل والإرضاع:<br />من غير المعروف إذا كان أدينوريكم يؤذي جنينك. لا ينبغي استعمال أدينوريكم في<br />خلال فترة الحمل. من غير المعروف إذا كان أدينوريكم ينتقل إلى حليب الثدي. لا<br />يجدر بك استعمال أدينوريكم إذا كنتِ تُرضعين أو إذا كنتِ تنوين الإرضاع.<br />إذا كنت حاملاً أو تقومين بالإرضاع أو تعتقدين أنك قد تكونين حاملاً أو تخططين<br />لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />قيادة السيّارات واستعمال الآلات:<br />يجب أن تعرف أنّك قد تُصاب بدوار وبنعاس وبعدم وضوح الرؤية وبشعور بالخدر<br />أو بالوخز في خلال مدّة العلاج وبالتالي لا يجدر بك قيادة سيّارة أو تشغيل آلة في حال<br />أُصبت بهذه العوارض.</strong></p><p dir="RTL"><strong>يحتوي أدينوريكم على اللاكتوز:<br />تحتوي أقراص أدينوريكم على اللاكتوز (نوع من السكر). إذا قيل لك إنّك تعاني<br />من عدم تحمّل بعض أنواع السكّر اتصل بطبيبك قبل أخذ هذا الدواء.المرضى الذين<br />يعانون من مشاكل وراثية نادرة من عدم تحمل الجلاكتوز أو نقص في أنزيم اللاب<br />لاكتازأو سوء امتصاص الجلوكوز - الجلاكتوز لا يجب أن يتناولوا هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">خذ دائمًا هذا الدواء حسب وصفة طبيبك تمامًا. إسأل طبيبك أو الصيدلي إذا لم تكن<br />متأكّدًا.<br />تبلغ الجرعة العاديّة قرصًا واحدًا في اليوم.<br />يجب أخذ الأقراص عن طريق الفم ويمكن أخذها مع الطعام أو بدونه.<br />- النّقرس<br />يأتي أدينوريكم إمّا على شكل قرص من ۸۰ ملغرام أو على شكل قرص من ۱۲۰<br />ملغرام. لقد وصف لك طبيبك العيار الأكثر ملاءمة لك.<br />واصل أخذ أدينوريكم كلّ يوم حتّى عندما لا تكون مصابًا بنوبة نقرس.<br />- الوقاية من ارتفاع مستويات حمض اليوريك وعلاجه لدى المرضى الذين يخضعون<br />للعلاج الكيميائي للسرطان.<br />يعطى أدينوريكم على شكل قرص من ۱۲۰ ملغرام.<br />إبدأ بأخذ أدينوريكم قبل العلاج الكيميائي بيومين وواصل استعماله وفقًا لإرشادات<br />طبيبك. عادة ما يكون العلاج قصير الأمد.<br />الشريط المحززعلى قرص ال ۸۰ ملغرام موجود فقط لمساعدتك على كسر القرص<br />اذا كنت تواجه صعوبة في ابتلاعه بالكامل.<br />إذا أخذت جرعة مفرطة من أدينوريكم:<br />في حال أخذت جرعة مفرطة عرضيًا إسأل طبيبك ما الذي عليك فعله أو اتصل بأقرب<br />قسم حوادث وطوارئ.<br />إذا نسيت أخذ أدينوريكم:<br />إذا فوّت جرعة من أدينوريكم خذها حالما تتذكّر إلاّ إذا كان سيحين وقت جرعتك<br />التالية، ففي هذه الحالة فوّت الجرعة التي نسيتها وخذ جرعتك التالية في وقتها المعتاد.<br />لا تأخذ جرعة مضاعفة للتعويض عن الجرعة التي فوّتها.<br />إذا توقّفت عن أخذ أدينوريكم:<br />لا تتوقّف عن أخذ أدينوريكم بدون استشارة طبيبك حتّى ولو كنت تشعر بتحسّن. إذا<br />توقّفت عن أخذ أدينوريكم قد تبدأ مستويات حمض البوليك لديك بالارتفاع وقد تتفاقم<br />عوارضك بسبب تشكّل بلّورات جديدة من اليورات في داخل مفاصلك وكليتيك أو<br />حولها.<br />إذا كان لديك أسئلة إضافيّة حول استعمال هذا الدواء، اطرحها على الطبيب أو<br />الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلّها، قد يسبّب هذا الدواء تأثيرات جانبيّة لا تصيب المرضى كلّهم.</p><p dir="RTL">توقّف عن أخذ هذا الدواء واتصل بطبيبك على الفور أو توجّه إلى أقرب قسم للطوارئ<br />إذا حصلت التأثيرات الجانبيّة النادرة (تصيب شخصًا من أصل ۱۰۰۰ شخص) التالية<br />لأنّ ارتكاسًا تحسسيًا حادًا قد يتبعها:<br />- ردود فعل تحسسيّة، فرط حساسيّة ضدّ الدواء (راجع أيضًا القسم ۲ التحذيرات<br />والاحتياطات)<br />- حالات من الطفح الجلدي قد تهدّد الحياة وتتميّز بتشكّل بثور وبذرف من الجلد ومن<br />الأسطح الداخليّة لتجاويف الجسم مثلاً من الفم والأعضاء التناسليّة، وبتقرّحات مؤلمة<br />في الفم و/أو في الأعضاء التناسليّة مع حمى والتهاب الحلق وتعب (متلازمة ستيفنز-<br />جونسون/ تقشّر الانسجة المتموتة البشروية التسممي)، أو بسبب تضخّم العقد اللمفاويّة<br />وتضخّم الكبد والتهاب الكبد (يصل إلى القصور الكبدي) وارتفاع في تعداد كريات الدم<br />(DRESS &ndash; البيض في الدم (ارتكاس دوائي مع فرط حمضات وعوارض مجموعيّة<br />( (راجع القسم ۲<br />- طفح جلدي معمم<br />التأثيرات الجانبيّة الشائعة (قد تصيب شخصًا من أصل ۱۰ أشخاص) هي: نتائج غير<br />طبيعيّة لفحوصات الكبد، إسهال، صداع، طفح، (بما في ذلك أنواع مختلفة من الطفح<br />&laquo; التأثيرات الجانبية غير الشائعة &raquo; الجلدي، يرجى الرجوع إلى القسمين أدناه<br />غثيان، ازدياد عوارض النقرس، وتورّم موضعي ،(&laquo; التأثيرات الجانبية النادرة &raquo; و<br />بسبب احتباس السوائل في الأنسجة (وذمة).<br />إن التأثيرات الجانبية الأخرى التي لم يرد ذكرها أعلاه مذكورة أدناه.<br />التأثيرات الجانبيّة غير الشائعة (قد تصيب شخصًا من أصل ۱۰۰ شخص) هي:<br />- قلّة الشهيّة، تغيير في مستويات السكر في الدم (داء السكري) قد يكون من عوارضه<br />الظمأ الشديد وازدياد مستويات الدهون في الدم وازدياد الوزن<br />- فقدان الرغبة الجنسيّة<br />- صعوبة في النوم، نعاس<br />- دوار، خدر، وخز، ضعف أو تغيير في الإحساس (نقص الحسّ، فالج نصفي خفيف<br />أو التنمّل)، تغيير أو ضعف في حاسة الذوق، نقص في حاسّة الشّم (ضعف الشّم)<br />- مخطط غير طبيعي لكهربائيّة القلب، عدم انتظام أو تسارع دقّات القلب، الشعور<br />بدقات القلب (خفقان)<br />- تورّد أو توهّج (مثلاً احمرار الوجه أو العنق)، ارتفاع ضغط الدم، نزف (فقط لدى<br />المرضى الذين يتلقّون علاجًا كيميائيًا لاضطرابات الدم).<br />- سعال، ضيق نفس، انزعاج أو ألم في الصدر، التهاب مجرى الأنف و/أو الحلق<br />(عدوى الجهاز التنفسي العلوي)، التهاب شعبي<br />- جفاف الفم، ألم / إنزعاج في البطن أو ريح، حرقة في المعدة / عسر هضم، إمساك،<br />زيادة إخراج البراز، تقيّؤ، انزعاج في المعدة<br />- حكّة، شرى، التهاب الجلد أو تغيّر لونه، بقعة صغيرة حمراء أو أرجوانيّة اللون<br />على الجلد، بقع صغيرة مسطّحة حمراء على الجلد، مساحة حمراء مسطّحة على الجلد<br />مغطّاة بنتوءات متجمّعة صغيرة، طفح، مساحات حمراء وبقع على الجلد ونوع آخر<br />من الاضطرابات الجلديّة<br />- مغص عضلي، ضعف عضلي، ألم / وجع في العضلات / المفاصل، التهاب كيسي<br />أو التهاب المفاصل (التهاب في المفاصل يرافقه عادة ألم وتورّم و/أو تيبّس)، ألم في</p><p dir="RTL">الأطراف، ألم في الظهر، تشنّج عضلي<br />- دم في البول، كثرة تبوّل غير طبيعيّة، فحوصات بول غير طبيعيّة (زيادة مستوى<br />البروتين في البول)، ضعف في قدرة الكلى على العمل كما يجب<br />- تعب، ألم في الصدر، انزعاج في الصدر<br />- حصى في المرارة أو في القنوات الصفراويّة (تحصّ صفراوي)<br />TSH - ارتفاع في مستوى الهورمون المحفّز للغدّة الدرقيّة في الدم<br />- تغييرات في كيمياء الدم أو في كميّة خلايا الدم أو الصفيحات (نتائج غير طبيعيّة<br />لفحوصات الدم)<br />- حصى كلويّة<br />- صعوبات في الانتصاب<br />التأثيرات الجانبيّة النادرة (قد تصيب شخصًا من أصل ۱۰۰۰ شخص) هي:<br />- ضرر عضلي وهي حالة يمكن أن تكون خطيرة في حالات نادرة. قد تسبّب هذه<br />الحالة مشاكل في العضلات وبخاصة إذا كنت تشعر بتوعّك في الوقت نفسه أو كانت<br />حرارتك مرتفعة، قد يكون سببها انهيار عضلي غير طبيعي. اتصل بطبيبك على الفور<br />إذا شعرت بألم أو وجع أو ضعف في العضلات.<br />- تورّم حاد في الطبقات الجلديّة العميقة بخاصة حول الشفتين أو العينين أو الأعضاء<br />التناسليّة أو اليدين أو القدمين أو اللسان مع احتمال التعرّض لصعوبة في التنفّس.<br />- حمّى بالتزامن مع طفح جلديّ بشبه الحصبة وتضخّم العقد اللمفاويّة وتضخّم الكبد<br />والتهاب الكبد (يصل إلى القصور الكبدي) وارتفاع في تعداد كريات الدم البيض في<br />الدم (زيادة عدد الكريات البيض مع أو بدون فرط حمضات).<br />- احمرار الجلد (الحمامى)، أنواع مختلفة من الطفح (مثلاً طفح يسبّب الحكّة، طفح مع<br />بقع بيضاء، طفح مع بثور، طفح مع بثور تحتوي على القيح، طفح مع ذرف من الجلد،<br />طفح شبيه بالحصبة)، حمامى واسعة الانتشار، نخر وانقلاع فقاعي في الجلد والأغشية<br />المخاطيّة يؤدّي إلى تقشّر واحتمال الإصابة بإنتان (متلازمة ستيفنز-جونسون) /تقشّر<br />الانسجة المتموتة البشروية التسممي<br />- عصبيّة<br />- شعور بالظمأ<br />- طنين في الأذنين<br />- عدم وضوح الرؤية، تغيير في الرؤية<br />- تساقط الشعر<br />- تقرّح الفم<br />- التهاب البنكرياس: العوارض الشائعة هي ألم البطن والغثيان والتقيّؤ<br />- زيادة التعرّق<br />- انخفاض في الوزن، زيادة الشهيّة، فقدان للشهيّة لا يمكن التحكّم به (فقدان الشهيّة)<br />- تيبّس في العضلات و/أو المفاصل<br />- تعداد منخفض لخلايا الدم بشكل غير طبيعي (الكريات البيض أو الحمر أو<br />الصفيحات)<br />- حاجة ملحّة للتبوّل<br />- تغييرات أو انخفاض في كميّة البول بسبب التهاب الكلى (التهاب الكلية الخلالي<br />النُبيبي)<br />- التهاب الكبد</p><p dir="RTL">- اصفرار الجلد (يرقان)<br />- ضرر كبديّ<br />- ارتفاع مستوى فوسفوكيناز الكرياتين في الدم (مؤشرعلى تلف العضلات)<br />- الموت القلبي المفاجئ<br />في حال تفاقم أحد التأثيرات الجانبيّة أو إذا لاحظت أيّ تأثيرات جانبيّة غير مذكورة في<br />هذه النشرة، الرجاء أن تُعلم الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحفظ بعيدًا عن متناول الأطفال ونظرهم.<br />يحفظ في العبوة الأساسية.<br />يحفظ في درجات حرارة لا تتعدى ۳۰ درجة مئويّة.<br />لا يُستعمل بعد انقضاء تاريخ الصلاحيّة المدوّن على علبة الكرتون وعلى ظرف<br />الأقراص. يشير تاريخ انتهاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.<br />لا ينبغي رمي الأدوية في المياه المبتذلة أو مع النفايات المنزليّة. إسأل الصيدليّ عن<br />كيفيّة التخلّص من الأدوية التي لم تعد بحاجة اليها، فمن شأن هذه الإجراءات حماية<br />البيئة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفاعلة هي الفيبوكسوستات.</p><p dir="RTL">يحتوي كلّ قرص على 80 ملغرام أو 120 ملغرام من الفيبوكسوستات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكوّنات الأخرى هي:</p><p dir="RTL">قلب القرص: لاكتوز مونوهيدرات، سلولوز دقيق البلوريّة، ستيارات المغنيزيوم، هيدروكسيبروبيل السلولوز، كروسكارميلوز صوديوم، سيليكا غروانيّة مميّهة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">غلاف القرص: أصفر أوبادراي 2، 85F42129 يحتوي على: بوليفينيل الكحول، ثاني أكسيد التيتانيوم (E171)، ماكروغول 3350، طلق وأكسيد الحديد الأصفر (E172).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف هو شكل أدينوريك<sup>م</sup>&nbsp;ومحتويات العلبة</strong></p><p dir="RTL">أقراص أدينوريك<sup>م</sup>&nbsp;المطليّة الغشاء هي صفراء باهتة إلى صفراء اللون وشكلها كالكبسولة.</p><p dir="RTL">أقراص الـ 80 ملغرام المطليّة الغشاء تحمل علامة &lsquo;80&rsquo; على جهة منها</p><p dir="RTL">وشريط محزز على الجهة الأخرى.</p><p dir="RTL">أقراص الـ 120&nbsp; ملغرام المطليّة الغشاء تحمل علامة &lsquo;120&rsquo; على جهة واحدة.</p><p dir="RTL">يأتي أدينوريك<sup>م</sup>&nbsp;في ظرفين من 14 قرصًا (علبة من 28 قرصًا).</p><p dir="RTL">قد لا تكون أحجام العلب كلّها مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق والمصنع المسؤول عن تحرير الصنف:<br />ألغوريتم ش.م.ل ذوق مصبح، لبنان<br />الشركة المصنعة:<br />الغوريتم ش.م.ل. ذوق مصبح ، لبنان<br />بإذن من تايجين فارما ش.م.م ، طوكيو، اليابان<br />أدينوريك هو علامة تجاريّة لتايجين ش.م.م ، طوكيو، اليابان</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ADENURIC 80 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 80 mg of febuxostat.
Excipient(s) with known effects:
Each tablet contains 76.50 mg of lactose (as monohydrate)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with “80” on one side and a break line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).<br />ADENURIC is indicated in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology<br />The recommended oral dose of ADENURIC is 80 mg once daily without regard to food. If serum uric acid is &gt; 6 mg/dL (357 &mu;mol/L) after 2-4 weeks, ADENURIC 120 mg once daily may be considered.<br />ADENURIC works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 &mu;mol/L).<br />Gout flare prophylaxis of at least 6 months is recommended (see section 4.4).<br />Elderly<br />No dose adjustment is required in the elderly (see section 5.2).<br />Renal impairment<br />The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min, see section 5.2).<br />No dose adjustment is necessary in patients with mild or moderate renal impairment.<br />Hepatic impairment<br />The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment<br />(Child Pugh Class C).</u></p><p><u>The recommended dose in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.<br />Paediatric population<br />The safety and the efficacy of ADENURIC in children aged below the age of 18 years have not been established. No data are available.<br />Method of administration<br />Oral use<br />ADENURIC should be taken by mouth and can be taken with or without food.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see also section 4.8).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Cardio-vascular disorders<br />Treatment with febuxostat in patients with pre-existing major cardiovascular diseases (e.g. myocardial infarction, stroke or unstable angina) should be avoided, unless no other therapy options are appropriate.<br />A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints<br />from the Anti-Platelet Trialists&#39; Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure.<br />In the post registrational CARES trial (see section 5.1 for detailed characteristics of the study) the rate of MACE events was similar in febuxostat versus allopurinol treated patients (HR 1.03; 95% CI 0.87-1.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73).<br />Medicinal product allergy / hypersensitivity<br />Rare reports of serious allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock, have been collected in the post-marketing experience. In most cases, these reactions occurred during the first month of therapy with febuxostat. Some, but not all of these patients reported renal impairment and/or previous hypersensitivity to allopurinol. Severe hypersensitivity reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated with fever, haematological, renal or hepatic involvement in some cases.<br />Patients should be advised of the signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment should be</em></p><p><em>immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis. If patient has developed allergic/hypersensitivity reactions including Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must not be re-started in this patient at any time.<br />Acute gouty attacks (gout flare)<br />Febuxostat treatment should not be started until an acute attack of gout has completely subsided. Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see section 4.8 and 5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2).<br />If a gout flare occurs during febuxostat treatment, it should not be discontinued. The gout flare should be managed concurrently as appropriate for the individual patient. Continuous treatment with febuxostat decreases frequency and intensity of gout flares.<br />Xanthine deposition<br />In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. As there has been no experience with febuxostat, its use in these populations is not recommended.<br />Mercaptopurine/azathioprine<br />Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine as inhibition of xanthine oxidase by febuxostat may cause increased plasma concentrations of mercaptopurine/azathioprine that could result in severe toxicity. No interaction studies have been performed in humans.<br />Where the combination cannot be avoided, a reduction of the dose of mercaptopurine or azathioprine is recommended. Based on modelling and simulation analysis of data from a pre-clinical study in rats, when co-administered with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.5 and 5.3).<br />The patients should be closely monitored and the dose of mercaptopurine/azathioprine should be subsequently adjusted based on the evaluation of the therapeutic response and the onset of eventual toxic effects.<br />Organ transplant recipients<br />As there has been no experience in organ transplant recipients, the use of febuxostat in such patients is not recommended (see section 5.1).<br />Theophylline<br />Co-administration of febuxostat 80 mg and theophylline 400mg single dose in healthy subjects showed absence of any pharmacokinetic interaction (see section 4.5). Febuxostat 80 mg can be used in patients concomitantly treated with theophylline without risk of increasing theophylline plasma levels. No data is available for febuxostat 120 mg.<br />Liver disorders<br />During the combined phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). Liver function test is recommended prior to the initiation of therapy with febuxostat and periodically thereafter based on clinical judgment (see section 5.1).</em></p><p><em>Thyroid disorders<br />Increased TSH values (&gt;5.5 &mu;IU/mL) were observed in patients on long-term treatment with<br />febuxostat (5.5%) in the long term open label extension studies. Caution is required when febuxostat is used in patients with alteration of thyroid function (see section 5.1).<br />Lactose<br />Febuxostat tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the<br />Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Mercaptopurine/azathioprine<br />On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these drugs leading to toxicity. Drug interaction studies of febuxostat with drugs(except theophylline) that are metabolized by XO have not been performed in humans.<br />Modelling and simulation analysis of data from a pre-clinical study in rats indicates that, in case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose ( see section 4.4 and 5.3).<br />Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted. No data is available regarding the safety of febuxostat during other cytotoxic therapy.<br />Rosiglitazone/CYP2C8 substrates<br />Febuxostat was shown to be a weak inhibitor of CYP2C8 in vitro. In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo. Thus, co-administration of febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment<br />for those compounds.<br />Theophylline<br />An interaction study in healthy subjects has been performed with febuxostat to evaluate whether the inhibition of XO may cause an increase in the theophylline circulating levels as reported with other XO inhibitors. The results of the study showed that the co-administration of febuxostat 80 mg QD with theophylline 400 mg single dose has no effect on the pharmacokinetics or safety of theophylline. Therefore no special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.<br />Naproxen and other inhibitors of glucuronidation<br />Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen 250 mg twice daily was associated with an increase in f ebuxostat exposure (Cmax 28%, AUC 41% and t1/2 26%). In clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically significant increase in adv erse ev ents.</em></p><p><em>Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.<br />Inducers of glucuronidation<br />Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.<br />Colchicine/indometacin/hydrochlorothiazide/warfarin<br />Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.<br />No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.<br />No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin in healthy subjects. INR and Factor VII activity were also not affected by the coadministration of febuxostat.<br />Desipramine/CYP2D6 substrates<br />Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro. In a study in healthy subjects,<br />120 mg ADENURIC QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo. Thus, co-administration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.<br />Antacids<br />Concomitant ingestion of an antacid containing magnesium hydroxide and aluminium hydroxide has been shown to delay absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in Cmax, but no significant change in AUC was observed. Therefore, febuxostat may be taken without regard to antacid use.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy<br />Data on a very limited number of exposed pregnancies have not indicated any adverse effects of febuxostat on pregnancy or on the health of the foetus/new born child. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development or parturition (see section 5.3). The potential risk for human is unknown. Febuxostat should not be used during pregnancy.<br />Breastfeeding<br />It is unknown whether febuxostat is excreted in human breast milk. Animal studies have shown excretion of this active substance in breast milk and an impaired development of<br />suckling pups. A risk to a suckling infant cannot be excluded. Febuxostat should not be used while breastfeeding.<br />Fertility<br />In animals, reproduction studies up to 48 mg/kg/day showed no dose-dependent adverse effects on fertility (see section 5.3). The effect of ADENURIC on human fertility is unknown.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of Febuxostat. Patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that ADENURIC does not adversely affect performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile </em></p><p>&nbsp;</p><p>The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema. These adverse reactions were mostly mild or moderate in severity. Rare serious hypersensitivity reactions to febuxostat, some of which were associated to systemic symptoms, and rare events of sudden cardiac death have occurred in the post-marketing experience.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Tabulated list of adverse reactions </em></p><p>&nbsp;</p><p>Common ( &ge;1/100&nbsp; to &lt;1/10), uncommon ( &ge;1/1,000 to &lt;1/100) and rare (&ge;1/10,000 to &lt;1/1,000) adverse reactions occurring in patients treated with febuxostat are listed below.</p><p>&nbsp;</p><p>Within each frequency&nbsp; grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><em>Table 1: Adverse reactions in combined phase 3, long-term extension studies and postmarketing experience&nbsp; </em></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><u>Rare:</u></p><p>Pancytopenia, thrombocytopenia, agranulocytosis*</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><u>Rare:</u></p><p>Anaphylactic reaction*, drug hypersensitivity*</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Endocrine disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Blood thyroid stimulating hormone increased</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Eye disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Blurred vision</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><u>Common***</u></p><p>Gout flares</p><p><u>Uncommon</u></p><p>Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase</p><p><u>Rare</u></p><p>Weight decrease, increase appetite, anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Libido decreased, insomnia</p><p><u>Rare</u></p><p>Nervousness</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Headache</p><p><u>Uncommon</u></p><p>Dizziness, paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p><u>Rare</u></p><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Atrial fibrillation, palpitations, ECG abnormal</p><p><u>Rare</u></p><p>Sudden cardiac death*</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Hypertension, flushing, hot flush</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory system disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Dyspnoea, bronchitis, upper respiratory tract infection, cough</p></td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;<u>Common:</u></p><p>Diarrhoea**, nausea</p><p><u>Uncommon</u></p><p>Abdominal pain, abdominal distension, gastro-oesophageal reflux disease, vomiting , dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort</p><p><u>Rare</u></p><p>Pancreatitis, mouth ulceration</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary&nbsp; disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Liver function abnormalities**&nbsp;</p><p><u>Uncommon </u>&nbsp;</p><p>Cholelithiasis</p><p><u>Rare</u></p><p>Hepatitis,&nbsp; jaundice* , liver injury*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><u>Common</u></p><p>Rash (including various types of rash reported with lower frequencies, see below)</p><p><u>Uncommon</u></p><p>Dermatitis, urticaria, pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash maculopapular, rash papular&nbsp;</p><p><u>Rare</u></p><p>Toxic epidermal necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with eosinophilia and systemic symptoms*, generalized rash (serious)*, erythema, exfoliative rash, rash follicular, rash vesicular, rash pustular, rash pruritic*, rash erythematous, rash morbillifom, alopecia, hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp; and connective tissue disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Arthralgia, arthritis, myalgia, musculoskeletal&nbsp; pain, muscle weakness, muscle spasm, muscle tightness, bursitis</p><p><u>Rare</u></p><p>Rhabdomyolysis*, joint stiffness, musculoskeletal stiffness</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Renal failure, nephrolithiasis,&nbsp; haematuria, pollakiuria, proteinuria <u>Rare</u></p><p>Tubulointerstitial&nbsp; nephritis*, micturition urgency</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorder</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><u>Common </u>&nbsp;</p><p>Oedema&nbsp;</p><p><u>Uncommon</u></p><p>Fatigue, chest pain, chest discomfort</p><p><u>Rare</u></p><p>Thirst</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p><u>Uncommon</u></p><p>Blood amylase increase, platelet count decrease, WBC decrease, lymphocyte count decrease, blood creatine increase, blood creatinine&nbsp; increase,&nbsp; haemoglobin decrease, blood&nbsp; urea increase, blood triglycerides increase, blood cholesterol increase, haematocritic decrease, blood lactate dehydrogenase increased, blood potassium increase</p><p><u>Rare</u></p><p>Blood glucose increase, activated partial thromboplastin&nbsp; time prolonged, red blood cell count decrease, blood alkaline phosphatase increase, blood creatine phosphokinase increase*</p></td></tr></tbody></table><p>&nbsp;</p><p>*Adverse reactions coming from post-marketing experience</p><p>** Treatment-emergent non-infective diarrhoea and abnormal liver function tests in the combined Phase 3 studies are more frequent in patients concomitantly treated with colchicine.</p><p>***See section 5.1 for incidences of gout flares in the individual Phase 3 randomized controlled studies.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Description of selected adverse reactions </em></p><p><em>&nbsp;</em></p><p>Rare serious hypersensitivity reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal necrolysis and anaphylactic reaction/shock, have occurred in the postmarketing experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are characterised by progressive skin rashes associated with blisters or mucosal lesions and eye irritation. Hypersensitivity reactions to febuxostat can be associated to the following symptoms: skin reactions characterised by infiltrated maculopapular eruption, generalised or exfoliative rashes, but also skin lesions, facial oedema, fever, haematologic abnormalities such as thrombocytopenia and eosinophilia, and single or multiple organ involvement (liver and kidney including tubulointerstitial nephritis) (see section 4.4).</p><p>&nbsp;</p><p>Gout flares were commonly observed soon after the start&nbsp; of treatment and during the first&nbsp; months. Thereafter, the frequency of gout flare decreases in a time-dependent manner.&nbsp; Gout flare prophylaxis is recommended (see section 4.2 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To report any side effect(s):Saudi Arabia:</p><p>o&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC): o Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext 2317-2356-2340 o SFDA Call Center: 19999 o E-mail: npc.drug@sfda.gov.sa o Website: <u>https://ade.sfda.gov.sa/</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; o &nbsp;&nbsp; Please contact the relevant competent authority</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients with an overdose should be managed by symptomatic and supportive care.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antigout preparation, preparations inhibiting uric acid production, ATC code:M04AA03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Uric acid is the end product of purine&nbsp; metabolism in humans&nbsp; and is generated in the cascade&nbsp; of hypoxanthine &rarr; xanthine &rarr; uric acid. Both steps&nbsp; in the above&nbsp; transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves&nbsp; its therapeutic effect&nbsp; of &nbsp;decreasing serum&nbsp; uric acid by selectively inhibiting XO. Febuxostat is a potent, nonpurine selective inhibitor of XO (NP-SIXO) with an <em>in vitro </em>inhibition Ki value less than one nanomolar. Febuxostat has been shown&nbsp; to potently&nbsp; inhibit both the oxidized and reduced&nbsp; forms&nbsp; of XO. At therapeutic concentrations febuxostat does not inhibit other&nbsp; enzymes&nbsp; involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine&nbsp; nucleoside phosphorylase.</p><p>&nbsp;</p><p><u>Clinical&nbsp; efficacy&nbsp; and safety</u></p><p>&nbsp;</p><p>The efficacy of ADENURIC was demonstrated in three Phase 3 pivotal&nbsp; studies&nbsp; (the two pivotal&nbsp; APEX and FACT&nbsp; studies, and the additional CONFIRMS study&nbsp; described below)&nbsp; that were conducted in 4101 patients&nbsp; with hyperuricaemia and gout. In each phase 3 pivotal study,&nbsp; ADENURIC demonstrated superior&nbsp; ability to lower and maintain serum&nbsp; uric acid levels&nbsp; compared to allopurinol. The primary efficacy&nbsp; endpoint in the APEX and FACT studies&nbsp; was the proportion of patients&nbsp; whose last 3 monthly serum uric acid levels were &lt; 6.0 mg/dL&nbsp; (357 &micro;<s>.</s>mol/L). In the additional phase 3 CONFIRMS study, for which results&nbsp; became&nbsp; available after the marketing authorisation for ADENURIC was first issued, the primary&nbsp; efficacy endpoint was the proportion of patients whose serum&nbsp; urate level was &lt; 6.0 mg/dL at the final visit. No patients&nbsp; with organ transplant have been included in these studies&nbsp; (see section 4.2).</p><p>&nbsp;</p><p><em>APEX Study: </em>The Allopurinol and Placebo-Controlled Efficacy Study&nbsp; of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study.&nbsp; One thousand and seventy-two (1072) patients&nbsp; were randomized: placebo (n=134),</p><p>ADENURIC 80 mg QD (n=267), ADENURIC 120 mg QD (n=269), ADENURIC 240</p><p><!--[if gte vml 1]><v:group id="Group_x0020_59006"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:32.4pt;margin-top:223pt;width:.7pt;height:13.8pt;z-index:251658240;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
 coordsize="9144,175564" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_63927" o:spid="_x0000_s1027" style='position:absolute;
  width:9144;height:175564;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,175564" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,175564l,175564,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,175564"/>
 </v:shape><w:wrap type="square" anchorx="page" anchory="page"/>
</v:group><![endif]--><img width="1" height="18" src="file:///C:/Users/14118/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />mg QD (n=134) or allopurinol (300 mg QD [n=258] for patients&nbsp; with a baseline serum&nbsp; creatinine &le;1.5 mg/dL or 100 mg QD [n=10] for patients with a baseline serum creatinine &gt;1.5 mg/dL and &le;2.0 mg/dL). Two hundred and forty mg febuxostat (2 times&nbsp; the recommended highest dose) was used as a safety evaluation dose.</p><p>The APEX study showed statistically significant superiority of both the ADENURIC 80 mg QD and the ADENURIC 120 mg QD treatment arms&nbsp; <em>versus </em>the conventionally used doses of allopurinol 300 mg (n = 258) /100 mg (n = 10) treatment arm in reducing the sUA below&nbsp; 6 mg/dL (357 &micro;mol/L) (see Table&nbsp; 2 and Figure 1).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>FACT Study: </em>The Febuxostat Allopurinol Controlled Trial (FACT)&nbsp; Study&nbsp; was a Phase 3, randomized, double-blind, multicenter, 52-week study.&nbsp; Seven hundred&nbsp; sixty (760)&nbsp; patients&nbsp; were randomized: ADENURIC 80 mg QD (n=256), ADENURIC 120 mg QD (n=251),&nbsp; or allopurinol300 mg QD (n=253).</p><p>&nbsp;</p><p>The FACT study showed the statistically significant superiority of both ADENURIC 80 mg and ADENURIC 120 mg QD treatment arms <em>versus </em>the conventionally used dose of allopurinol 300 mg treatment arm in reducing and maintaining sUA below&nbsp; 6 mg/dL&nbsp; (357 &micro;mol/L).</p><p>Table 2 summarizes the primary efficacy endpoint results:&nbsp;</p><p><strong>Table 2 </strong></p><p><strong>Proportion of Patients with Serum Uric Acid Levels &lt; 6.0 mg/dL (357 &mu;mol/L) </strong></p><p><strong>Last Three Monthly Visits </strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td><p>Study</p></td><td><p>ADENURIC 80 mg QD</p></td><td><p>ADENURIC 120 mg QD</p></td><td style="vertical-align:top"><p>Allopurinol</p><p>300/</p><p>100 mg QD<sup>1 </sup></p></td></tr><tr><td style="vertical-align:top"><p>APEX</p><p>(28 weeks)</p></td><td style="vertical-align:top"><p>48% <sup>* </sup></p><p>(n=262)</p></td><td style="vertical-align:top"><p>65% *,# (n=269)</p></td><td style="vertical-align:top"><p>22% <sup>* </sup></p><p>(n=268)</p></td></tr><tr><td style="vertical-align:top"><p>FACT</p><p>(52 weeks)</p></td><td style="vertical-align:top"><p>53% <sup>* </sup></p><p>(n=255)</p></td><td style="vertical-align:top"><p>62% <sup>* </sup></p><p>(n=250)</p></td><td style="vertical-align:top"><p>21% <sup>* </sup></p><p>(n=251)</p></td></tr><tr><td style="vertical-align:top"><p>Combined Results</p></td><td style="vertical-align:top"><p>51% <sup>* </sup></p><p>(n=517)</p></td><td style="vertical-align:top"><p>63% *,# (n=519)</p></td><td style="vertical-align:top"><p>22% <sup>* </sup></p><p>(n=519)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>1 </sup>results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine &gt; 1.5 and &le; 2.0 mg/dL) or 300 mg QD (n= 509) were pooled for analyses.</p><p>* p &lt; 0.001 vs allopurinol , <sup># </sup>&nbsp;p &lt; 0.001 vs 80 mg</p></td></tr></tbody></table><p>&nbsp;</p><p>The ability of ADENURIC to lower serum uric acid levels was prompt and persistent.</p><p>Reduction in serum uric acid level to &lt;6.0 mg/dL (357 &mu;mol/L) was noted by the Week 2 visit and was maintained&nbsp; throughout treatment. The mean serum uric acid levels over time for each treatment group from the two pivotal Phase 3 studies are shown in Figure 1.</p><p>&nbsp;</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Note: 509 patients received allopurinol 300 mg QD; 10 patients with serum creatinine&gt;1.5 and&lt;&le;2.0 mg/dL were dosed with 100 mg QD. (10 patients out of 268 in APEX study). 240 mg febuxostat was used to evaluate the safety of febuxostat at twice the recommended highest dose.</p><p>&nbsp;</p><p>CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol&nbsp; 300 mg or 200 mg, in patients with gout and hyperuricaemia. Two thousand and two hundred-sixty&nbsp; nine (2269) patients were randomized: ADENURIC 40 mg QD (n 757), ADENURIC 80 mg QD (n 756), or allopurinol 300/200 mg QD (n 756). At least 65% of the patients had mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min). Prophylaxis against gout flares was obligatory over the 26-week period. The proportion of patients with serum urate levels of&lt; 6.0 mg/dL (357 &micro;mol/L) at the final visit, was&nbsp; 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.</p><p>&nbsp;</p><p><em>Primary endpoint in the sub- group of patients with renal impairment</em></p><p>The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine&gt; 1.5 mg/dL and &le;2.0 mg/dL). For renally impaired subjects who were randomized to allopurinol, the dose was capped at 100 mg QD. ADENURIC achieved the primary efficacy endpoint in 44% (80 mg QD), 45% ( 120 mg QD), and 60% (240 mg QD) of patients compared to 0% in the allopurinol 100 mg QD and placebo groups.</p><p>&nbsp;</p><p>There were no clinically significant differences in the percent decrease in serum uric acid concentration in healthy subjects irrespective of their renal function (58% in the normal renal function group and 55% in the severe renal dysfunction group).</p><p>&nbsp;</p><p>An analysis in patients with gout and renal impairment was prospectively defined in the CONFIRMS study, and showed that febuxostat was significantly&nbsp; more efficacious in lowering serum urate levels to &lt; 6 mg/dL compared to allopurinol 300 mg/200 mg in patients who had gout with mild to moderate renal impairment (65% of patients studied).</p><p>&nbsp;</p><p><em>Primary endpoint in the sub group of patients with sUA </em>&ge; <em>10 mgldL</em></p><p>Approximately 40% of patients (combined APEX and FACT) had a baseline sUA of &ge; 10 mg/dL. In this subgroup ADENURIC achieved the primary efficacy endpoint (sUA&lt; 6.0 mg/dL at the last 3 visits) in 41% (80 mg QD), 48% (120 mg QD), and 66% (240 mg QD) of patients compared to 9% in the allopurinol 300 mg/100 mg QD and 0% in the placebo groups.</p><p>&nbsp;</p><p>In the CONFIRMS study, the proportion of patients achieving the primary efficacy endpoint (sUA &lt; 6.0 mg/dL at the final visit) for patients with a baseline serum urate level of &ge; 10 mg/dL treated with febuxostat 40 mg QD was 27% (66/249), with febuxostat 80 mg QD</p><p>49% (125/254) and with allopurinol 300 mg/200 mg QD 31% (72/230), respectively.</p><p>&nbsp;</p><p>Clinical Outcomes: proportion of patients requiring treatment for a gout flare</p><p>&nbsp;</p><p>APEX study: During the 8-week prophylaxis period, a greater proportion of subjects in the Febuxostat 120 mg (36%) treatment group required treatment for gout flare compared to febuxostat 80 mg (28%), allopurinol 300 mg (23%) and placebo (20%). Flares increased following the prophylaxis period and gradually decreased over time. Between 46% and 55% of subjects received treatment for gout flares from Week 8 and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were observed in 15% (febuxostat&nbsp; 80, 120 mg),</p><p>14% (allopurinol 300 mg) and 20% (placebo) of subjects.</p><p>&nbsp;</p><p>FACT study: During the 8-week prophylaxis period, a greater proportion of subjects in the Febuxostat 120 mg (36%) treatment group required treatment for a gout flare compared to both the Febuxostat 80 mg (22%) and allopurinol 300 mg (21%) treatment groups. After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks 49-52) were observed in 6-8% (febuxostat</p><p>80 mg, 120 mg) and 11% (allopurinol300 mg) of subjects.</p><p>&nbsp;</p><p>The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically&nbsp; lower in the groups that achieved an average post-baseline serum urate level &lt;6.0 mg/dL, &lt;5.0 mg/dL, or &lt;4.0 mg/dL compared to the group that achieved an average post-baseline serum urate&nbsp; level &ge;6.0 mg/dL during the last 32 weeks of the treatment period</p><p>(Week 20-Week 24 to Week 49- 52 intervals).</p><p>&nbsp;</p><p>During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively. No difference in the proportion of patients requiring treatment for gout flares was observed between the febuxostat 80 mg and 40 mg groups.</p><p>&nbsp;</p><p>Long-term, open label extension Studies</p><p>EXCEL Study (C02-021): The Excel study was a three years Phase 3, open label, multicenter, randomised, allopurinol-controlled, safety extension study for patients who had completed the pivotal Phase 3 studies (APEX or FACT).&nbsp; A total of 1,086 patients were enrolled: ADENURIC 80 mg QD (n=649), Adenuric 120 mg QD (n=292) and allopurinol300/100 mg QD (n=145). About 69% of patients required no treatment change to achieve a final stable treatment. Patients who had 3 consecutive sUA levels &gt;6.0 mg/dL were withdrawn.</p><p>Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment&nbsp; with febuxostat 80 mg and 120 mg, respectively, had sUA &lt;6 mg/dL at Month 36).</p><p>&nbsp;</p><p>Three years data showed a decrease in the incidence of gout flares with less than 4% of patients requiring treatment for a flare (i.e. more than 96% of patients did not require treatment for a flare) at Month 16-24 and at Month 30-36.</p><p>&nbsp;</p><p>46% and 38%, of patients on final stable treatment of febuxostat 80 or 120 mg QD, respectively, had complete resolution of the primary palpable tophus from baseline to the Final Visit.</p><p>&nbsp;</p><p>FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004.</p><p>116 patients were enrolled and received&nbsp; initially febuxostat 80 mg QD. 62% of patients required no dose adjustment to maintain sUA &lt;6 mg/dL and 38% of patients required a dose adjustment to achieve a final stable dose.</p><p>The proportion of patients with serum urate levels of &lt;6.0 mg/dL (357 &micro;mol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.</p><p>&nbsp;</p><p>During the phase 3 clinical studies, mild liver function test abnormalities were observed in patients treated with febuxostat (5.0%). These rates were similar to the rates reported on allopurinol (4.2%) (see section 4.4). Increased TSH values (&gt;5.5&micro;IU/mL) were observed in patients on long-term treatment with febuxostat (5.5%) and patients with allopurinol (5.8%) in the long term open label extension studies (see section 4.4).</p><p>&nbsp;</p><p><em>Post Marketing long term studies </em></p><p><em>&nbsp;</em></p><p>CARES Study was a multicenter, randomized, double-blind, non inferiority trial comparing CV outcomes with febuxostat versus allopurinol in patients with gout and a history of major CV disease including MI, hospitalization for unstable angina, coronary or cerebral revascularization procedure, stroke, hospitalized transient ischemic attack, peripheral vascular disease, or diabetes mellitus with evidence of microvascular or macrovascular disease. To achieve sUA less than 6 mg/dL, the dose of febuxostat was titrated from 40 mg up to 80 mg (regardless of renal function) and the dose of allopurinol was titrated in 100 mg increments from 300 to 600 mg in patients with normal renal function and mild renal impairment and from 200 to 400 mg in patients with moderate renal impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects, maximum plasma concentrations (Cmax) and area under the plasma concentration time curve (AUC) of febuxostat increased in a dose proportional manner following single and multiple doses of 10 mg to 120 mg. For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat. There is no appreciable accumulation when doses of<br />10 mg to 240 mg are administered every 24 hours. Febuxostat has an apparent mean terminal elimination half-life (t1/2) of approximately 5 to 8 hours.<br />Population pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with hyperuricaemia and gout, treated with ADENURIC 40-240 mg QD. In general, febuxostat pharmacokinetic parameters estimated by these analyses are consistent with those obtained from healthy subjects, indicating that healthy subjects are representative for pharmacokinetic/pharmacodynamic assessment in the patient population with gout.<br />Absorption<br />Febuxostat is rapidly (tmax of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral<br />80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 &mu;g/mL, and 5.0-5.3 &mu;g/mL, respectively. Absolute bioavailability of the febuxostat tablet formulation has not been studied.<br />Following multiple oral 80 mg once daily doses or a single 120 mg dose with a high fat meal, there<br />was a 49% and 38% decrease in Cmax and a 18% and 16% decrease in AUC, respectively. However, no clinically significant change in the percent decrease in serum uric acid concentration was observed where tested (80 mg multiple dose). Thus, ADENURIC may be taken without regard to food.<br />Distribution<br />The apparent steady state volume of distribution (Vss/F) of febuxostat ranges from 29 to 75 L after oral doses of 10-300 mg. The plasma protein binding of febuxostat is approximately 99.2%, (primarily to albumin), and is constant over the concentration range achieved with 80 and 120 mg doses. Plasma protein binding of the active metabolites ranges from about 82% to 91%.<br />Biotransformation<br />Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl metabolites have been identified, of which three occur in plasma of humans. In vitro studies with human liver microsomes showed that those oxidative metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was<br />formed mainly by UGT 1A1, 1A8, and 1A9.<br />Elimination<br />Febuxostat is eliminated by both hepatic and renal pathways. Following an 80 mg oral dose of 14Clabeled<br />febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%). In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).</p><p>Renal impairment<br />Following multiple doses of 80 mg of ADENURIC in patients with mild, moderate or severe renal impairment, the Cmax of febuxostat did not change, relative to subjects with normal renal function. The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 -&mu;g&middot;h/mL in the normal renal function group to 13.2 &mu;g.h/mL in the severe renal dysfunction group. The Cmax and AUC of active metabolites increased up to 2- and 4-fold, respectively. However, no dose adjustment is necessary in patients with mild or moderate renal impairment.<br />Hepatic impairment<br />Following multiple doses of 80 mg of ADENURIC in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the Cmax and AUC of febuxostat and its metabolites did not change significantly compared to subjects with normal hepatic function. No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C).<br />Age<br />There were no significant changes observed in AUC of febuxostat or its metabolites following multiple oral doses of ADENURIC in elderly as compared to younger healthy subjects.<br />Gender<br />Following multiple oral doses of ADENURIC, the Cmax and AUC were 24% and 12% higher in females than in males, respectively. However, weight-corrected Cmax and AUC were similar between the genders. No dose adjustment is needed based on gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were generally observed at exposures in excess of the maximum human exposure.<br />Pharmacokinetic modelling and simulation of rat data suggests that, when co-administered with febuxostat, the clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less of the previously prescribed dose in order to avoid possible haematological effects (see section 4.4 and 4.5).<br />Carcinogenesis, mutagenesis, impairment of fertility<br />In male rats, a statistically significant increase in urinary bladder tumours (transitional cell papilloma and carcinoma) was found only in association with xanthine calculi in the high dose group, at approximately 11 times human exposure. There was no significant increase in any other tumour type in either male or female mice or rats. These findings are considered a consequence of species specific purine metabolism and urine composition and of no relevance to clinical use.<br />A standard battery of test for genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat.<br />Febuxostat at oral doses up to 48 mg/kg/day was found to have no effect on fertility and reproductive performance of male and female rats.<br />There was no evidence of impaired fertility, teratogenic effects, or harm to the foetus due to febuxostat. There was high dose maternal toxicity accompanied by a reduction in weaning index and reduced development of offspring in rats at approximately 4.3 times human exposure. Teratology studies, performed in pregnant rats at approximately 4.3 times and pregnant rabbits<br />at approximately<br />13 times human exposure did not reveal any teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core </em></p><p>Lactose monohydrate</p><p>Microcrystalline cellulose Magnesium stearate</p><p>Hydroxypropylcellulose</p><p>Croscarmellose sodium</p><p>Silica, colloidal hydrated</p><p>&nbsp;</p><p><em>Tablet coating </em></p><p>Opadry II, Yellow, 85F42129 containing:</p><p>Polyvinyl alcohol</p><p>Titanium dioxide (E171)</p><p>Macrogols 3350</p><p>Talc</p><p>Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear (Aclar/PVC/Aluminium or PVC/PE/PVDC/Aluminium) blister of 14 tablets.</p><p>&nbsp;</p><p>ADENURIC 80 mg is available in pack sizes of 14, 28, 42, 56, 84 and 98 film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Algorithm S.A.L- Lebanon
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>